Agonists of the TRAIL death receptor DR5 sensitize intestinal stem cells to chemotherapy-induced cell death and trigger gastrointestinal toxicity

The combination of TRAIL death receptor agonists and radiochemotherapy to treat advanced cancers continues to be investigated in clinical trials. We previously showed that normal cells with a functional DNA damage response (DDR) upregulate the expression of death inducing receptor DR5/TRAILR2/TNFRSF...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Finnberg, Niklas K., Gokare, Prashanth, Navaraj, Arunasalam, Lang Kuhs, Krystle A., Cerniglia, George, Yagita, Hideo, Takeda, Kazuyoshi, Motoyama, Noboru, El-Deiry, Wafik S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001853/
https://ncbi.nlm.nih.gov/pubmed/26609054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-2759
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares